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wall and peak videointensity (PVI) was measured in gray levels. Results * =
p < 0.01 for EG vs DIP + EG.
HR FA(S) FA (D) LV PA PVI
BASE 145 ± 23 172 ± 14 120 ± 7 165 ± 12 122 ± 6 23 ± 18
EG 150 ± 24 163 ± 13 114±7 159 ± 13 28± 10 69 ± 50
DIP 142 ± 19 171 ± 14 114 ± 15 162 ± 23 24 ± 3 33 ± 21
DIP + EG 145 ± 23 156 ± 31 99 ± 21 145 ± 32 32 ± 4 110 ± 41
1. Anteroseptal
2. Anterior
3. Lateral
4. Posterolateral
5. Inferior
6. Posteroseptal
Pre-Occlusion
46.65 ± 7.01
3248 ± 1260
15.12 ± 4.39
12.13 ± 377
23.59 ± 4.62
45.21 ± 1105
Post-Occlusion
1.87 ± 2.17'
0.04 ± 5.01'
26.29 ± 843
13.43 ± 5.95
20.80 ± 9.25
19.56 ± 5.05
Reperfusion
44.17 ± 399
34.37 ± 498
5.52 ± 915
14.79 ± 455
7.58 ± 7.02
18.02 ± 410
'p < 0.001
Thus, combination of antihistamine-steriod pretreatment and dipyridamole
vasodilation enables enhanced visualization of myocardial perfusion by re-
duced doses of EG without significant hemodynamic effects. This approach
may be of value in achieving myocardial opacification in patients with EG
without incurring side effects.
As the data showed, after LAD occlusion anteroseptal (1) and anterolat-
eral (2) segments showed a statistically significant loss (*p < 0.001) of their
preocclusion contrast echo VD change and it was recovered following reper-
fusion. In our study, MRX provided visual and VD delineation of myocardium
at risk and changes induced by reperfusion after IV injection.
Thus, the ultrasound contrast agent FS069 results in measurable, con-
sistent, and reproducible myocardial opacification when administered intra-
venously.
Howard C. Dittrich, Gary L. Bales, Britta A McFerran, Mary T. Kuvelas, Roberta
M. Hunt. Yigal Greener University of California, San Diego, CA; Molecular Biosysterns,
Inc. San Diego, CA
In order for myocardial contrast echocardiography to become clinically use-
ful, ultrasound contrast agents must result in reproducible opacification. We
therefore studied a new agent capable of producing myocardial opacification
when given intravenously. FS069, proteinaceous, gas-filled microspheres
(mean size range: 3.6-5.4 micron, concentration: 6.3-9.0 x 108/m11. was
administered to 10 closed-chest anesthetized dogs (20-29 kgl in doses of
0.4--0.7 ml at a rate of 0.3 mllsec into an internal jugular or cephalic vein.
Total volumes/dog were 28-54 ml. Transthoracic, parasternal short axis im-
ages were acquired using a Hewlett Packard Sonos 1500 and time-intensity
curves from gated images were generated from the anterior, septal, and lat-
eral left ventricular walls and cavity with an on-line system. The increase in
mean pixel intensity compared to baseline was measured. No changes in
heart rate, systemic blood pressure, or arterial blood gases attributable to
FS069 were detected. Myocardial opacification in multiple segments was
documented in 100% of injections. There was no significant difference in in-
tensity change between injections although there was a difference between
myocardial segments within the same injection.
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'p < 0.01 compared to PESDA
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Large concentrations of intravenous (IV) albumin microbubbles are capable
of producing visual anterior myocardial contrast (MC). This also results in
high left ventricular cavity contrast which prevents visualization of posterior
myocardium due to attenuation. Recently, MC following intravenous soni-
cated dextrose albumin has been possible by altering microbubble (MB) gas
composition to one with lower blood solubility and diffusivity due to their
higher molecular weight (MW). Since this preserves MB size in blood, we hy-
pothesized that lower doses of this contrast could produce the same MC ef-
fect with less cavity attenuation following intravenous injection. Accordingly,
we sonicated dextrose albumin with two different gases of different MW:
an evaporated fluorocarbon gas (perfluoropentane: MW 270 grams/mole
(PPSDA); or perfluoropropane MW 188 g/mole (PESDA)). A total of 30 intra-
venous doses of 0.015-0.060 mllkg of the two different samples were given
to open chest dogs under baseline conditions, during adenosine infusion
(140Ikg/min), during acute ischemia produced by a left circumflex stenosis
or occlusion, and finally during subsequent reperfusion of the circumflex ves-
sel. The peak myocardial videointensity (PMVI) and duration (in seconds) of
attenuation (AD) in the posterior wall of these two agents were compared.
PMVI in the anterior (AW) and posterior wall (PW) were measured following
each injection, as were left circumflex and left anterior descending flow rates
with a Transonic Doppler. Values are mean ± standard deviation:
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Cavity
16.8 ± 66
16.4±7.0
0.99"
2.2 ± 15
2.1 ± 2.4
0.86'
Lateral
05 ± 0.6 52 ± 4.6
0.5 ± 0.6 4.9 ± 4.5
0.48 0.94"
Anterior Septal
Intensity Change (mean ± SD)
Injection 1, dB
Injection 2, dB
1 vs. 2, r
, < 0.01," < 0001
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The availability of new contrast agents capable of transpulmonary, left ven-
tricular and myocardial opacification after intravenous injection warrants
evaluation of their efficacy for assessing abnormalities of myocardium per-
fusion and results of intervention. In the present study, open chest epicardial
echocardiography(7 MHz)was performed during intravenous administration
of MRX 115, a new lipid contrast agent at a dose of 0.02 or 0.05 mllkg in 6
instrumented monkeys before and after acute LAD ligation and following
reperfusion. Visually apparent myocardial opacification was evident in all an-
imals for all IV injections of MRX before LAD occlusion without significant
hemodynamic effect. After LAD occlusion, a "filling defect" overlapping the
area with abnormal wall motion could be delineated and uptake of subse-
quently injected contrast could be demonstrated within 10 to 20 minutes fol-
lowing release of LAD occlusion. The peak videodensitometric (VD) changes
(256 unit scale) from baseline after IV MRX injection over each of 6 areas of
coronary perfusion areas on the LV short axis before and after LAD occlusion
and 20 minutes following release are shown (mean ± SE):
IV PPSDABaseline
Both agents produced visua/Iy evident and similar anterior myocardial con-
trast, but PESDA caused prolonged posterior wall attenuation and failed to
produce significant posterior wall contrast. The dextrose albumin sonicated
with the gas of highest MW (PPSDA) produced significantly higher posterior
wall contrast (see example) which also improved the detection of area at risk
during LCX ischemia. We conclude that dextrose albumin sonicated with an
evaporated larger molecular weight fluorocarbon gas results in (a) improved
myocardial contrast of the posterior leftventricularwall with significantly less
attenuation; and (b) visual determination of the area at risk during posterior
ischemia.
Intracardiac Echocardiographic Quantification
and Monitoring of Myocardial Perfusion Defects
and Repertusion with the Use of Intravenous
Injection of FS069, a Transpulmonic Contrast
Agent
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Contrast Echocardiographic Assessment of
Myocardial Pertusion Following Acute Coronary
Artery Occlusion and Repertusion Using
Intravenous Injection of Aerosome,. MRX 115 in
Monkeys
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Despite major efforts, echocardiographic delineation of LV myocardial hy-
